Clinical Trial: Primary Aldosteronism In Hypertensive Patients in China
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational
Official Title: Primary Aldosteronism In Hypertensive Patients in China
Brief Summary: To investigate the prevalence of primary aldosteronism (PA) in Chinese patients with hypertension.
Detailed Summary: This is a nationwide sampling study. To investigate the prevalence of primary aldosteronism (PA) in Chinese patients with hypertension, we will conduct a case detection of PA in Chinese hypertensive patients from 10 centers of China (including Beijing, Chongqing, Shanghai, Guangzhou, et al.); furthermore, a case confirmation of PA (captopril challenge test and saline infusion test) will be performed if the result of case detection is positive. This study will be completed in two years.
Sponsor: Qifu Li
Current Primary Outcome:
- Number of subjects with newly diagnosed hypertension [ Time Frame: 2 years ]To calculate the prevalence of PA in Chinese patients with hypertension
- Number of subjects with confirmed primary aldosteronism (PA) [ Time Frame: 2 years ]To calculate the prevalence of PA in Chinese patients with hypertension
- Prevalence of PA [ Time Frame: 2 years ]Prevalence of PA= Number of PA / Number of subjects with hypertension
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Age [ Time Frame: 2 years ]Characteristics of PA in Chinese patients with hypertension
- Blood pressure [ Time Frame: 2 years ]Characteristics of PA in Chinese patients with hypertension
- Family history of hypertension [ Time Frame: 2 years ]Characteristics of PA in Chinese patients with hypertension
- Fasting blood glucose [ Time Frame: 2 years ]Characteristics of PA in Chinese patients with hypertension
- Cardiovascular events [ Time Frame: 2 years ]Characteristics of PA in Chinese patients with hypertension
Original Secondary Outcome: Same as current
Information By: Chongqing Medical University
Dates:
Date Received: April 28, 2017
Date Started: June 3, 2017
Date Completion: April 30, 2019
Last Updated: May 13, 2017
Last Verified: May 2017